Cargando…
Pembrolizumab‐axitinib‐induced tumor lysis syndrome in a patient with metastatic renal cancer
Tumor lysis syndrome is uncommon in solid tumors but with the use of immunotherapy (checkpoint inhibitors) their incidence is increasing. Physicians need to take adequate precautions while treating patients with immunotherapy. The findings of our case report will help improve our current understandi...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141709/ https://www.ncbi.nlm.nih.gov/pubmed/32274041 http://dx.doi.org/10.1002/ccr3.2737 |